Analysis of purine-and pyrimidine-induced vascular responses in the isolated rat cerebral arteriole. Am J Physiol Heart Circ Physiol 280: H767-H776, 2001.-Effects of extraluminal UTP were studied and compared with vascular responses to ATP and its analogs in rat cerebral-penetrating arterioles. UTP, UDP, 2-methylthio-ATP, and ␣,␤-methylene-ATP dilated arterioles at the lowest concentration and constricted them at high concentrations. Low concentrations of ATP dilated the vessels; high concentrations caused a biphasic response, with transient constriction followed by dilation. Endothelial impairment inhibited ATP-and UTP-mediated dilation and potentiated constriction to UTP but not to ATP. ATP-and 2-methylthio-ATP-but not UTP-mediated constrictions were inhibited by desensitization with 10 Ϫ6 M ␣,␤-methylene-ATP or 3 ϫ 10 Ϫ6 M pyridoxal phosphate-6-azophenyl-2Ј,4Ј-disulfonic acid (PPADS). PPADS at 10 Ϫ4 M abolished the UTPmediated constriction and induced vasodilation in a dosedependent manner but did not affect the dilation to ATP. These results suggest that in rat cerebral microvessels 1) ATP and 2-methylthio-ATP induce transient constriction via smooth muscle P 2X1 receptors in the cerebral arteriole, 2) UTP stimulates two different classes of P 2Y receptors, resulting in constriction (smooth muscle P 2Y4 ) and dilation (possibly endothelial P 2Y2 ), and 3) ATP and UTP produce dilation by stimulation of a single receptor (P 2Y2 ).
PURINES SUCH AS ATP and pyrimidines such as UTP are involved in many important regulatory systems (6, 39, 53) . In the cerebral circulation, ATP and UTP are natural agonists with prominent vasoactivity and numerous physiological sources (8, 19, 22, 30, 40, 41, 43, 44) . Although ATP was initially found to cause vasodilation and UTP was a strong vasoconstrictor, further studies showed that ATP and UTP can cause dilation, constriction, or both, depending on the species, vessel type, location within the vascular tree, and/or route of administration (14, 20, 25, 26, 38-41, 48, 50, 54, 60, 61) . This variability in responses can be explained by purines and pyrimidines acting on a number of different receptors that can reside on the vessel's smooth muscle and/or endothelial cells, with their distribution also variable along the vascular tree ( Table 1) . P 2 receptors have been divided into two broad groups: ionotropic P 2X receptors, which are intrinsic ion channels, and metabotropic P 2Y receptors, which are G protein coupled (3, 46) and may activate different phospholipases (11) . In the vasculature, P 2X1 receptors on smooth muscle mediate constriction via Ca 2ϩ influx (Table 1) (46, 59) . P 2Y receptors were found on endothelial cells of several vessel types causing dilation via activation of P 2Y1 (P 2Y ) and P 2Y2 (P 2U ) receptors. On smooth muscle, P 2Y2 -, P 2Y4 -, and P 2Y6 -receptor activation causes constriction, while similar stimulation of the P 2Y1 receptor induces vessel dilation (3, 46) .
Only recently have studies appeared elucidating purinergic vasomotor responses and receptor distribution in cerebral vessels (Table 1 ). In dog cerebral arteries, ATP, coreleased from perivascular sympathetic nerves, stimulates P 2X1 receptors, causing transient constriction (39, 40) . However, in rat cerebral arteries, ATP causes endothelium-dependent dilation through P 2Y2 receptors, while 2-methylthio-ATP (2-MeSATP) induces dilation through P 2Y1 receptors (60) . Constriction induced by stimulation of P 2X1 receptors by ␣,␤-methylene-ATP (␣,␤-MetATP) was less effective than that induced by ATP (60) . In rat cerebral artery and bovine middle cerebral artery, UTP acts on endothelial and smooth muscle P 2Y2 receptors, with stimulation of the endothelial receptors directly causing dilation (60) or opposing smooth muscle-induced vasoconstriction (38) . In large cerebral vessels, ATP and UTP appear to act predominantly through endothelial P 2Y2 receptors (60) , with the smooth muscle possibly contracting via P 2Y2 receptors in addition to P 2X1 receptors (Table 1) .
In cerebral microvessels, purinergic receptor distribution has not been identified. However, several studies found that ATP elicits vasodilator and vasoconstrictor responses after intra-or extraluminal administration in vivo and in vitro (14, 25-27, 34, 49, 61) . Tested only in mouse, UTP constricted pial arterioles in vivo independent of the endothelium (48, 50) .
Since vessel reactivity to agonists changes along the cerebrovascular tree (61) , extrapolation of the results obtained from the macrocirculation to microvessels could be problematic. Penetrating cerebral arterioles, which originate from pial vessels and supply the cerebral cortex, represent the last smooth muscle vessels before the blood is distributed into the capillary bed. These vessels may contribute as much as 23% of the total arterial cerebrovascular resistance (47) , making them an important regulator of cerebral blood flow. Since little is known about the distribution of purinergic receptors on these important resistance vessels, we evaluated vasomotor responses to extraluminal UTP and compared them with those induced by ATP using isolated, pressurized cerebral-penetrating arterioles of the rat. We used P 2 -purinoceptor antagonists and agonists to elucidate pharmacologically the type of P 2 purinoceptor involved in the purinergic transmission in these vessels (Table 1) . To differentiate between smooth muscle-and endothelium-mediated responses, we impaired endothelial function using air embolization in some vessels.
MATERIALS AND METHODS
Preparation and cannulation. Studies were approved by the Washington University Animal Studies Committee. The procedure for preparation and cannulation has been described previously (13, 14) . Briefly, male Sprague-Dawley rats (n ϭ 49), weighing 383 Ϯ 9 g, were anesthetized with pentobarbital sodium (65 mg/kg ip) and killed. The brain was removed and transferred to a dissection chamber filled with physiological salt solution (PSS; 4°C; see below) with 1% BSA. A penetrating arteriole was isolated from the middle cerebral artery and transferred to a temperature-controlled organ bath (2.5 ml volume) mounted on the stage of a Nikon or Zeiss inverted microscope. The arteriole was cannulated at one end with glass pipettes. The other end was occluded. All experiments were conducted without intraluminal flow. The transmural pressure (60 mmHg) was monitored continuously with a pressure transducer (model P23, Gould, Cleveland, OH) and recorded on a strip chart recorder (model 3200, Gould). The internal diameter of the vessel was observed with a high-resolution videocamera (CCD 72 with GenIIsis, Dage-MTI, Michigan City, IN) and displayed on a monitor. The chamber temperature was increased to 37.5°C, and the vessels were allowed to develop spontaneous tone for 45 min at pH 7.3. The chamber was superfused with PSS without BSA at a constant flow rate (0.5 ml/min) with a peristaltic pump (model 203, Scientific Industries, Bohemia, NY). The arterioles developed spontaneous tone, and we assessed their responsiveness and viability by changing the extraluminal pH from 7.3 to 6.8 and from 7.3 to 7.65. We discarded vessels with poor tone (Ͻ20% decrease from the maximum diameter) or poor pH response (Ͻ15% diameter change). In some vessels, we compared vessel tone and pH-induced responses at the beginning and end of experiments to confirm the stability of the preparation.
Diameter measurements. We used a calibrated video-dimensional analyzer (modified model 321, Colorado Video, Boulder, CO) (13, 14) and computerized diameter tracking system (video resolution 320 ϫ 200 pixels with 256 shades of gray; Diamtrak, Montech) to measure the internal vessel diameter. The resolution of this tracking system was 0.5 m/pixel with a sample rate of 9-10 Hz. The data were recorded on a strip chart recorder and stored digitally.
Experimental protocols. In the first series of experiments, dose-response curves of UTP, UDP, ␣,␤-MetATP, and 2-MeSATP ranging from 10 Ϫ12 to 10 Ϫ4 M were obtained. UTP was used as P 2Y2 (P 2U )-, P 2Y4 -, and weaker P 2Y6 -subtype agonists (9, 42, 45, 46) . UDP is selective for the P 2Y6 subtype (42) , and ␣,␤-MetATP is selective for the P 2X1 subtype (28, 59 ). 2-MeSATP is a P 2Y1 (P 2Y )-and a P 2X1 -subtype agonist (Table 1) (45, 59) .
In the second series of experiments, the effects of functional endothelial disruption on UTP-and ATP-induced responses were investigated. The endothelium was impaired by passage of air through the arteriole at 60 mmHg intraluminal pressure. To assess endothelial damage, we superfused 5 ϫ 10 Ϫ6 M propidium iodide extraluminally before and after air embolism and counted stained endothelial and smooth muscle cells in the field of view. Staining of cell nuclei indicated cell damage, which we visualized using epifluorescence with a standard TRITC filter set. Air embolization does not necessarily remove the endothelium but has been shown to disrupt the endothelium in microvessels (52) . Only vessels that regained spontaneous tone after air embolization were accepted for data analysis. We used sodium nitroprusside (SNP) to ensure that vascular smooth muscle dilation was not changed before and after air embolization.
In the third series of experiments, 10 Ϫ6 M ␣,␤-MetATP was used to desensitize P 2X1 receptors (28, 46) . Dose-response curves of UTP and 2-MeSATP and responses to 10 Ϫ4 M ATP were conducted in the absence or presence of ␣,␤-MetATP. We also used 3 ϫ 10 Ϫ6 M pyridoxal phosphate 6-azophenyl-2Ј,4Ј-disulfonic acid (PPADS) as another P 2X1 antagonist (59) to analyze responses to 10 Ϫ4 M ATP, 10 Ϫ4 M UTP, 10 Ϫ4 M 2-MeSATP, and 10 Ϫ6 M ␣,␤-MetATP. In the fourth series of experiments, dose-response curves for UTP were obtained in the absence and presence of 10 Ϫ6 M suramin (a P 2 -purinoceptor antagonist) or 10 Ϫ4 M PPADS (a P 2X1 -and P 2Y -receptor antagonist) (9, 45, 46) . We also tested 10 Ϫ4 M ATP and compared its response with that of UTP. The incubation periods were Ն20 min for each antagonist.
Drugs and solutions. The composition of the PSS (in mmol/l) was as follows: 144 NaCl, 3 KCl, 2.5 CaCl 2 , 1.4 MgSO 4 , 2.0 pyruvate, 5.0 glucose, 0.02 EDTA, 2.0 MOPS, and 1.21 NaH 2 PO 4 . Solutions used for dissection and cannulation contained 1% BSA.
All drugs were obtained from Sigma Chemical (St. Louis, MO).
Statistical analysis. Only one vessel was studied from each rat brain. Experimental values represent means Ϯ SE; n indicates the number of vessels used in the present study. For dose-response curves, the data are presented as absolute diameter. To demonstrate the effect of antagonists or endothelial impairment on the vessel responses, we expressed the magnitude of constriction and dilation as percent changes from resting diameter (control before administration of drug defined as 0%) and compared the diameter changes before and after the inhibition. Statistically significant differences (P Ͻ 0.05) were determined by repeated-measures ANOVA with Bonferroni's multiple comparisons test as posttest or paired Student's t-test as appropriate.
RESULTS
The passive maximum vessel diameter of 49 cerebral arterioles was 65.7 Ϯ 1.4 m. The vessels developed spontaneous tone, constricting by 28.3 Ϯ 0.9% to an average diameter of 47.3 Ϯ 1.3 m. They dilated by 25.9 Ϯ 1.4% to pH 6.8 and constricted by Ϫ27.9 Ϯ 1.0% to pH 7.65.
Stability of the preparation. In six arterioles, the pH challenge was repeated at the end of experiment. The duration of the experiments was 180 Ϯ 22 min. We found no significant difference in vessel tone (32.3 Ϯ 2.9 and 33.4 Ϯ 4.4% at the beginning and end, respectively), acidosis-induced dilation (34 Ϯ 1.9 vs. 26 Ϯ 4.3%), and alkalosis-induced constriction (Ϫ28.2 Ϯ 1.5 vs. Ϫ29.0 Ϯ 3.3%).
Responses to P 2 -purinoceptor agonists. The concentration-response curves to UTP, UDP, 2-MeSATP, and ␣,␤-MetATP are shown in Fig. 1, A and B. Since the data for the UTP dose-response curves used in the second and fourth series did not differ statistically, we pooled these into the data shown in Fig. 1A . Representative traces of the vasomotor responses to these agonists are shown in Fig. 1C . UTP, UDP, 2-MeSATP, and ␣,␤-MetATP dilated arterioles at the lowest concentration (10 Ϫ12 M) and constricted them at higher concentrations (10 Ϫ4 and 10 Ϫ6 M, except for UDP at 10 Ϫ6 M; Fig. 1, A and B) . Furthermore, responses of these agonists were monophasic; i.e., only dilation or constriction was observed. The maximum dilations of UTP, UDP, 2-MeSATP, and ␣,␤-MetATP were 10.7 Ϯ 2.0% (n ϭ 23), 4.8 Ϯ 2.3% (n ϭ 6), 5.8 Ϯ 1.3% (n ϭ 10), and 7.6 Ϯ 5.9% (n ϭ 5), respectively, at 10 Ϫ12 M (P Ͻ 0.05 vs. control). The maximum constrictions to all agonists except ␣,␤-MetATP were observed at 10 Ϫ4 M.
For ␣,␤-MetATP, 10 Ϫ6 M induced maximum constriction. The maximum constriction values for UTP, UDP, 2-MeSATP, and ␣,␤-MetATP were Ϫ25.2 Ϯ 1.8% (n ϭ 23), Ϫ7.0 Ϯ 1.1% (n ϭ 6), Ϫ22.5 Ϯ 4.3% (n ϭ 10), and Ϫ17.3 Ϯ 2.0% (n ϭ 5), respectively. UDP was ϳ3.5-fold less potent than UTP. UTP-and UDP-induced constrictions were steady and sustained, while 2-MeSATP and ␣,␤-MetATP evoked only a temporary constriction (Fig. 1C) . There is a marked difference in the time course of the vasomotor effect of the pyrimidines (UTP and UDP) compared with the purine analogs (2-Me-SATP and ␣,␤-MetATP). We previously reported that, at high concentrations, extraluminal ATP evoked a biphasic response: initial temporary constriction (18%) followed by dilation (17%) (14, 27) (Figs. 1C and 2B) . None of the other agonists used in this study showed such dual behavior. This may indicate that ATP acts on different receptors/signal transduction pathways to elicit the various responses.
Effects of air emboli on ATP-and UTP-induced responses. Endothelial impairment by air embolization significantly constricted arterioles from 48.1 Ϯ 3.4 to 43.6 Ϯ 2.9 m (Ϫ9.4% of control diameter before air embolization), indicating endothelial disruption. Under control conditions, neither smooth muscle cells nor endothelial cells were stained by propidium iodide. After air embolization, 12.2 Ϯ 1.9 endothelial cells/250 m and 0.7 Ϯ 0.3 smooth muscle cells/250 m vessel length were stained with propidium iodide, indicating that predominantly endothelial cell damage had occurred ( Fig. 2A) . In five additional experiments, we applied the endothelium-independent nitric oxide donor SNP. The dilation in response to 10 Ϫ7 and 10 Ϫ5 M SNP (11.3 Ϯ 2.6 and 21.4 Ϯ 2.0% before air embolization vs. 11.8 Ϯ 2 and 19.5 Ϯ 0.9% after air embolization) was not altered by air embolization (n ϭ 5). ATP-induced initial constrictions were not altered by the endothelial impairment; however, secondary dilations were significantly inhibited (Fig. 2B) . Air embolization also attenuated UTP-mediated dilation and, in contrast to ATP, potentiated vessel constriction (Fig.  2C ). These results demonstrate that UTP and ATP dilate arterioles via endothelial stimulation and that UTP-but not ATP-mediated constriction is decreased by an intact endothelium.
Effects of P 2X1 -purinoceptor desensitization by ␣,␤-MetATP. ␣,␤-MetATP (10 Ϫ6 M) itself constricted the vessel transiently, with the arteriole subsequently returning to its control diameter (Fig. 1C) . ATP-and 2-MeSATP-induced constrictions were attenuated in the presence of 10 Ϫ6 M ␣,␤-MetATP, which indicates that P 2X1 -receptor stimulation is involved in the contractile response (Figs. 3A and 4) . In contrast, 10 Ϫ6 M ␣,␤-MetATP did not attenuate the dilation of 2-Me-SATP or ATP (Figs. 3A and 4) . The dose response of UTP was not affected by ␣,␤-MetATP (Fig. 3B) .
Effects of PPADS on vasoconstrictor and vasodilator responses. PPADS had no effect on the basal vessel diameter. PPADS at 3 ϫ 10 Ϫ6 M (P 2X1 -receptor antagonist at this concentration) significantly inhibited constrictions of 2-MeSATP, ␣,␤-MetATP, and ATP, but not H769 UTP (Figs. 5 and 6 ). These results further support that ATP, 2-MeSATP, and ␣,␤-MetATP, but not UTP, constrict the vessel through P 2X1 -receptor stimulation. The ATP-induced dilation was neither attenuated nor potentiated by 3 ϫ 10 Ϫ6 and 10 Ϫ4 M PPADS (Fig. 6 ).
However, in the presence of 10 Ϫ4 M PPADS (P 2X1 -and P 2Y -receptor antagonists at this concentration) (45, 46) , UTP-induced constrictions were reversed, with dilation occurring at high concentration (Fig. 7) .
Effects of suramin on ATP-and UTP-induced vasoconstriction and vasodilation. Suramin (10 Ϫ6 M) had no effect on the UTP-and ATP-induced responses (n ϭ 4, data not shown). We could not use higher concentrations of suramin (up to 10 Ϫ4 M), as used in other studies (36, 51) , because suramin induced vasodilation (data not shown).
DISCUSSION
The new findings in the present study are as follows:
1) The pyrimidines UTP and UDP and the ATP analogs 2-MeSATP and ␣,␤-MetATP applied extraluminally dilate isolated, pressurized rat cerebral-penetrating arterioles at the low concentration (10 Ϫ12 M) and constrict the vessels at high concentrations (Ͼ10 Ϫ6 M). 2) Constrictions induced by the pyrimidines UTP and UDP and the ATP analogs 2-MeSATP and ␣,␤-MetATP were monophasic; no biphasic response with initial constriction followed by a secondary dilation, as seen with ATP, occurred (Fig. 1C) (14, 27) . 3) UDP was ϳ3.5-fold less potent than UTP. 4) Using pharmacological tools and endothelial impairment, we suggest that ATP and 2-MeSATP induce transient constriction via smooth muscle P 2X1 -receptor stimulation. 5) UTP stimulates two P 2Y -receptor types, resulting in dilation via stimulation of endothelial P 2Y2 receptors and sustained constriction through smooth muscle P 2Y4 receptors. 6) ATP and UTP produce dilation by the same receptor stimulation, probably endothelial P 2Y2 .
Purine (ATP, 2-MeSATP, and ␣,␤-MetATP)-mediated vasoconstriction in cerebral arterioles. At high concentrations 2-MeSATP and ␣,␤-MetATP caused transient vasoconstriction similar to ATP (Fig. 1C) . However, 2-MeSATP and ␣,␤-MetATP did not cause a secondary dilation, as observed with ATP stimulation (Figs. 1C and 2B) (14, 27) . Constrictions induced by ATP, 2-MeSATP, and ␣,␤-MetATP were diminished after desensitization of the P 2X1 receptor by ␣,␤-MetATP or pretreatment with 3 ϫ 10 Ϫ6 M PPADS (Figs. 3A, 4 , and 5). Our results are consistent with ATP and 2-MeSATP mediating transient constrictions via stimulation of P 2X1 receptors. In addition, ATP mediates a secondary dilation that is not mimicked by 2-MeSATP or ␣,␤-MetATP, indicating that ATP also acts on other P 2 receptor(s). Our results are similar to those reported after sympathetic stimulation in dog cerebral artery (41) but differ from those found in isolated rat cerebral artery. In the latter studies, extraluminal ATP and 2-MeSATP caused a sustained constriction, while stimulation with ␣,␤-MetATP caused some constriction at 10 Ϫ6 M but a vasodilation at 10 Ϫ4 M (60). This would suggest that large cerebral vessel vasoconstriction is the result of stimulation of P 2X1 and P 2Y receptors, which differs from the results observed in smaller cerebral vessels.
Smooth muscle P 2X1 receptors are ligand-gated ion channels mediating constriction through activation of nonselective cation currents (Na
, resulting in increase of intracellular Ca 2ϩ and depolarization (46) . Depolarization leads to activation of voltage-dependent Ca 2ϩ channels, further increasing Ca 2ϩ influx (46) .
Purine-mediated vasodilation in cerebral arterioles. 2-MeSATP is a strong vasodilator of large cerebral arteries, possibly via endothelial P 2Y1 receptors (61) . In our study, extraluminal application of 2-MeSATP caused only a small vasodilation at lower concentration (Fig. 1B) . You and co-workers (61) reported that the intraluminal application of 2-MeSATP did not significantly dilate third-order branches of the middle cerebral artery and large penetrating arterioles of the rat, while it did induce a pronounced dilation of the middle cerebral artery. They hypothesized that this heterogeneity of 2-MeSATP-induced responses might result from an altered distribution or function of P 2Y1 receptors along the vascular tree.
Since 2-MeSATP can stimulate P 2X1 and P 2Y1 receptors, another possible explanation is that 2-MeSATP also stimulated P 2X1 receptors, thus counteracting a vasodilator P 2Y1 effect. In our experiments, 2-MeSATPmediated dilation was not potentiated after desensitization of P 2X1 receptors (Fig. 3A) . In addition, the ATP-induced dilation was unaffected by the desensitization of P 2X1 receptors (Fig. 4) , and endothelial impairment did not potentiate ATP-induced constrictions (Fig. 2B) . If stimulation of P 2X1 receptors were to counteract a vasodilator effect of 2-MeSATP and ATP in our preparations, agonist-induced dilation should be potentiated by the desensitization of P 2X1 receptors, and constriction should be enhanced after the endothelial impairment.
Our results indicate that transient constrictions by a high concentration of ATP and 2-MeSATP did not result from the competition between constriction and dilation. Thus ATP and 2-MeSATP probably stimulated and then desensitized P 2X1 receptors, causing the temporary constriction. Such desensitization has been previously reported in numerous tissues (39, 46) .
We suggest either that 2-MeSATP is not a potent agonist of P 2Y1 receptors in rat cerebral arterioles or that there is only a limited distribution of P 2Y1 recep- Fig. 2 . A: effects of air emboli on nuclear propidium iodide staining. After air embolization, propidium iodide stained predominantly endothelial cells (nuclei aligned parallel to vessel axis) but only few smooth muscle cells (nuclei arranged perpendicular to vessel axis). Nuclear staining indicates cell damage. B and C: effects of air emboli on ATP-and UTPinduced responses, respectively (n ϭ 4). ATP-induced dilation is significantly decreased after air embolization, while the constrictor response is unchanged. UTPinduced vasodilation is abolished, while the vasoconstriction is enhanced after endothelial disruption. †Significant decrease or increase (P Ͻ 0.05) of agonist-induced responses after air emboli.
tors on the endothelium. In either case, ATP does not dilate the cerebral arteriole through the P 2Y1 receptor in penetrating cerebral arterioles.
The small dilation produced by ␣,␤-MetATP at lower concentrations has been occasionally observed in the rat middle cerebral artery (60) and mouse pial arteriole (49) . Although the mechanism for this vasodilation is unclear, it is possible that low concentration of ␣,␤-MetATP might also stimulate P 2Y receptors.
Pyrimidine (UTP and UDP)-mediated vasomotor responses in cerebral arterioles. Recently, it has become apparent that initial tone and route of administration are important factors determining the magnitude and direction of vascular responses to UTP in vitro (20, 38, 59, 60) . In the rat middle cerebral artery, UTP induces a dose-dependent dilation with intraluminal administration or constriction with extraluminal administration (60) . UTP relaxed precontracted human pial artery strips at 10 Ϫ7 -10 Ϫ5 M and constricted them at high concentration (20) . Endothelial removal potentiated the UTP-induced constriction in human pial artery and bovine middle cerebral artery strips (20, 38) .
Little is known about vascular responses to pyrimidine nucleotides in the cerebral microcirculation. In our study, extraluminal UTP and UDP dilated rat cerebral arterioles at low concentrations and constricted them at high concentrations (Fig. 1A) . UTP (and UDP) dilated the penetrating arterioles at lower concentrations than those found with cerebral arteries (38, 60) . UTP-induced vasodilation was diminished and UTP-but not ATP-induced constrictions were potentiated after the endothelial impairment. These results indicate that UTP stimulated endothelial and smooth muscle P 2 purinoceptors and that the endothelium in penetrating arterioles appears to be more sensitive to pyrimidines than are larger cerebral vessels. Thus the UTP-induced smooth muscle constriction was opposed by an endothelial vasodilator effect. This could mean that high extraluminal UTP might be a strong constrictor after endothelial injury in pathophysiological states, including subarachnoid hemorrhage (55) .
Receptors involved in pyrimidine-induced vasoconstriction and vasodilation. There are marked differences in purine-and pyrimidine-induced constrictions with respect to receptor subtype, desensitization, and the release and inhibition of the other neurotransmitters (53, 58) . P 2X1 receptors are desensitized by purines such as ATP, while P 2Y receptors do not readily desensitize (46) .
In the present study, UTP-evoked constrictions in rat cerebral arterioles were resistant to desensitization and blockade of P 2X1 receptor by ␣,␤-MetATP and 3 ϫ 10 Ϫ6 M PPADS. The endothelial impairment diminished UTP-mediated dilations at low concentrations and potentiated the constriction at high concentrations (Fig. 2C) , with UTP-induced constriction abolished by 10 Ϫ4 M PPADS. Furthermore, 10 Ϫ4 M PPADS converted the UTP-induced constriction to a strong dilation (Fig. 7) . These results indicate that 1) UTP-evoked constriction is not due to the stimulation of P 2X1 receptors in the rat cerebral arteriole, 2) vascular responses to UTP result from the competition of endothelial and smooth muscle receptor stimulation, 3) 10 Ϫ4 M PPADS is an antagonist of UTP-induced constriction, and 4) UTP-induced dilation is not affected by 10 Ϫ4 M PPADS. Thus UTP appears to stimulate two distinct P 2Y -purinoceptor subtypes present simultaneously on the smooth muscle and endothelium.
Smooth muscle P 2Y2 -, P 2Y4 -, and P 2Y6 -receptor subtypes, working through the phospholipase C-inositol (1,4,5)-trisphosphate-Ca 2ϩ cascade, elicit pyrimidine nucleotide-induced constriction due to increase of intracellular Ca 2ϩ activity (3, 23, 46) . UDP is a strong P 2Y6 agonist (42) and a partial agonist at P 2Y2 and P 2Y4 receptors (4, 9, 42) , while UTP is a potent agonist at P 2Y2 and P 2Y4 receptors (9, 42) . In the present study, the rat cerebral-penetrating arterioles constricted less to UDP than to UTP, suggesting that the UTP-evoked constriction is not caused by stimulation of P 2Y6 receptors. Thus UTP-induced responses are probably more likely due to stimulation of P 2Y2 -and/or P 2Y4 -receptor subtypes.
High concentrations of PPADS are considered to act as a general P 2Y -receptor inhibitor. However, in several studies, PPADS inhibited only P 2Y1 , P 2Y4 , and, to a lesser degree, P 2Y6 receptors, but not P 2Y2 receptors (9, Fig. 6 . Effects of 3 ϫ 10 Ϫ6 and 10 Ϫ4 M PPADS on 10 Ϫ4 M ATPinduced constriction followed by dilation of rat cerebral arterioles (n ϭ 5). †Significantly different (P Ͻ 0.05) from control. PPADS at 10 Ϫ4 M completely abolished ATP-induced constriction but did not affect vessel dilation.
Fig. 7. Effects of 10
Ϫ4 M PPADS on UTP-induced dilation and constriction of rat cerebral arterioles (n ϭ 6). †Significant differences (P Ͻ 0.05) between control and inhibition with PPADS. PPADS at 10 Ϫ4 M reversed UTP-induced constriction to strong UTP-induced dilation. H773 10, 45, 46) . Our data would suggest that, in rat cerebral arterioles, UTP may induce constriction via activation of smooth muscle P 2Y4 receptors and dilation via endothelial P 2Y2 -receptor stimulation, respectively. We applied suramin, which may antagonize P 2Y2 receptors and not P 2Y4 receptors (4, 9, 46) . However, 10 Ϫ6 M suramin did not inhibit UTP-or ATP-mediated responses. These results suggest that suramin at this concentration does not antagonize P 2 purinoceptors in our preparation. Higher concentrations of suramin (up to 10 Ϫ4 M) (36, 51) and, similarly, reactive blue-2 (general P 2Y antagonist) (46) induced a strong vasodilation and thus could not be used in our experiments (data not shown). While the lack of a specific P 2Y2 antagonist in our preparation does not exclude an unknown mechanism involved in UTP-induced dilation, the results obtained with PPADS support that the observed dilation may be due to P 2Y2 -receptor stimulation.
To further substantiate that UTP causes constriction via P 2Y4 -receptor stimulation, we compared the vasoconstriction induced by UTP with that produced by ATP. UTP and ATP are considered to be equipotent agonists for P 2Y2 receptors (46) located on the endothelium and smooth muscle (3, 33, 50) . Stimulation of endothelial and smooth muscle P 2Y2 receptors causes dilation and constriction, respectively (3, 38, 51) . UTPand ATP-induced constrictions via P 2Y2 -receptor stimulation were reported in rat pulmonary (51) and bovine middle cerebral (38) arteries. In the present study, ATP caused constriction via P 2X1 but not P 2Y2 receptors (Fig. 4 and 6 ). This result supports the idea that UTPinduced constriction is mediated via P 2Y4 receptors, a finding similar to that reported in the canine epicardial coronary circulation (33) .
UTP-and ATP-mediated dilation in cerebral arterioles. P 2Y1 and P 2Y2 receptors are generally located on the endothelium, and their stimulation causes dilation (3, 46) . These receptors are G protein coupled, with the most common pathway for P 2Y -receptor signaling activation of phospholipase C leading to inositol (1,4,5)-trisphosphate release. This causes Ca 2ϩ mobilization and activation of protein kinase C, phospholipase A 2 , or Ca 2ϩ -dependent K ϩ channels, leading to the formation of an endothelial nitric oxide-or prostanoid-based relaxation factor depending on species and P 2y -receptor type studied (46) . However, it is interesting that there is also evidence for relaxation via smooth muscle P 2Y1 receptors in some blood vessels (12, 57) .
At low concentrations, UTP induced dilation in rat cerebral arterioles, which dose dependently increases in the presence of 10 Ϫ4 M PPADS. ATP-induced dilation following constriction was not inhibited by PPADS. Higher concentrations of PPADS (10 Ϫ5 -10 Ϫ4 M) have been used as P 2Y1 -receptor antagonists (45, 59) . These results suggest that 1) the receptor subtype mediating the dilation induced by UTP is different from that mediating the constriction induced by UTP and similar to that mediating the dilation induced by ATP and 2) UTP and ATP probably mediate dilations via endothelial P 2Y2 -receptor stimulation in the rat penetrating arteriole. In the cerebral circulation, release of nitric oxide and endothelium-derived hyperpolarizing factor, rather than prostacyclin, appears to be involved in the dilation to endothelial P 2Y1 -and P 2Y2 -receptor stimulation (25, 26, 38, 60, 61) . In rat cerebral artery, endothelial P 2Y1 stimulation causes exclusively nitric oxide release, while P 2Y2 stimulation released nitric oxide and another not yet defined relaxation factor (60) . In rat cerebral-penetrating arterioles, scavenging of nitric oxide with oxyhemoglobin reduced ATP-induced vasodilation at low but not at high concentrations (27) . These results indicate that, in these vessels, ATP may initially release nitric oxide at low ATP concentrations and another yet unidentified relaxation factor is released at high ATP concentrations. Second messenger systems, which may account for the observed difference in mediators released, have not been studied in the cerebral microcirculation. Sources for ATP and UTP and possible physiological relevance. Natural sources for ATP in the brain include corelease from perivascular sympathetic nerves to modulate pressor responses (40, 41) , which could overflow into the vessel lumen to elicit vasomotor responses downstream (2) . Release from cerebral nerves (30) may act on cerebral vessels directly via diffusion or indirectly through astrocyte stimulation (7, 21) . ATP is also released from red blood cells during hypoxia and/or acidosis, causing vasodilation (1, 16) , and may be a mechanism for sensing metabolic need in the tissue (1) . Platelets release basal amounts of ATP (22, 44) , which acts to inhibit platelet aggregation (56) via nitric oxide generation (37) , while platelet activation is associated with the release of large amounts of ATP (17) . Thus, in rat cerebral arterioles, intraluminal ATP may be mainly involved in maintaining blood flow by mediating hypoxic vasodilation and inhibiting platelet activation. Since ATP can diffuse from the vessel lumen to arteriolar smooth muscle cells (35) , transient smooth muscle constriction may counteract an overdilation due to large amounts of intraluminal ATP, preventing vessel damage. However, massive ATP release from brain tissue after trauma or platelet activation may have only a short-term effect on arteriolar vessel constriction (due to P 2X1 -receptor desensitization), while the large cerebral arteries would develop vasospasm due to smooth muscle P 2Y -receptor stimulation (32, 61) .
Cerebral sources for UTP are less well studied, and its physiological function is less well described (31) . UTP is likewise liberated from platelets (44) and has been shown to be released from neuronally derived tissue such as chromaffin cells (19) . Furthermore, UTP and ATP were found in high concentrations in synaptosomes of cerebral tissue (8, 43) , suggesting that ATP and UTP can be released into the tissue after trauma.
While a physiological function for ATP in the cerebral circulation is apparent (18, 29) , such a role for UTP is less clear. Our data show that UTP dilates penetrating arterioles at low concentrations. We speculate that UTP, similar to ATP, may be involved in maintaining local blood flow by preventing platelet H774 aggregation and countering smooth muscle tone. Pathologically, a massive release of UTP from brain tissue and/or platelets could be responsible for the vasospasm observed after cerebral injury and subarachnoid hemorrhage.
In conclusion, we analyzed the responses to UTP, ATP, and its analogs in the rat cerebral arteriole. ATP and 2-MeSATP induce temporary constriction via P 2X1 receptors on the smooth muscle cell. ATP-mediated dilation is due to endothelial P 2Y2 -receptor stimulation. In contrast, UTP causes sustained constriction at high concentrations and dilation at low concentrations. UTP probably activates P 2Y4 receptors in the smooth muscle cell, causing constriction, and P 2Y2 receptors on the endothelial cell, causing dilation. P 2Y4 -receptor stimulation of UTP may counteract the dilatory response of P 2Y2 receptors to UTP.
